Alexandria Venture Investments, LLC - Oct 21, 2021 Form 3 Insider Report for Xilio Therapeutics, Inc. (XLO)

Role
10%+ Owner
Signature
By: ALEXANDRIA REAL ESTATE EQUITIES, INC., a Maryland corporation, managing member By: /s/ Dean A. Shigenaga Chief Financial Officer
Stock symbol
XLO
Transactions as of
Oct 21, 2021
Transactions value $
$0
Form type
3
Date filed
10/21/2021, 08:59 PM
Previous filing
Jun 1, 2021
Next filing
Oct 26, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding XLO Series B convertible preferred stock Oct 21, 2021 Common stock 166K Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The preferred stock is convertible into the Issuer's common stock at a ratio of 9.5 shares of preferred stock to 1 share of common stock at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering, for no additional consideration.